CAR T cells and T cell engagers for autoimmunity—lessons from hematology

• by Sarah Kayser, Arnon Nagler

• February 23, 2026

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

• by Christen M. Dillard, Hans Lee, Nilesh Kalariya, Naveen Subramanian, Oren Pasvolsky, Christopher Ferreri, Mahmoud Gaballa, Sheeba K. Thomas, Donna M. Weber, Melody Becnel, Gregory Kaufman, Muzaffar Qazilbash, Robert Z. Orlowski, Michelle A. T. Hildebrandt, Krina K. Patel

• April 13, 2026

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

• April 27, 2026

• 6 min

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

• by Leo Rasche, Maria Theresa Krauth, Hermine Agis, Christoph Renner, Irene Strassl, Raphael Teipel, Vladan Vučinić, Katja Weisel, Wolfgang Willenbacher, Marc S. Raab

• May 13, 2026